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Abstract: Genome-Wide Association Studies (GWAS),
whole genome sequencing, and high-throughput omics
techniques have generated vast amounts of genotypic
and molecular phenotypic data. However, these data have
not yet been fully explored to improve the effectiveness
and efficiency of drug discovery, which continues along a
one-drug-one-target-one-disease paradigm. As a partial
consequence, both the cost to launch a new drug and the
attrition rate are increasing. Systems pharmacology and
pharmacogenomics are emerging to exploit the available
data and potentially reverse this trend, but, as we argue
here, more is needed. To understand the impact of
genetic, epigenetic, and environmental factors on drug
action, we must study the structural energetics and
dynamics of molecular interactions in the context of the
whole human genome and interactome. Such an ap-
proach requires an integrative modeling framework for
drug action that leverages advances in data-driven
statistical modeling and mechanism-based multiscale
modeling and transforms heterogeneous data from
GWAS, high-throughput sequencing, structural genomics,
functional genomics, and chemical genomics into unified
knowledge. This is not a small task, but, as reviewed here,
progress is being made towards the final goal of
personalized medicines for the treatment of complex
diseases.
Introduction
Drug discovery, as broadly practiced, suffers from several
shortcomings. First, although the vast amounts of genotypic and
molecular phenotypic data generated from Genome-Wide Asso-
ciation Studies (GWAS); whole genome sequencing (WGS) [1];
and high-throughput techniques such as RNA-seq [2], ChIP-seq
[3], BS-seq [4], and DNase-seq [5] provide an unprecedented
opportunity to understand the etiology of complex diseases and to
discover safe and potent personalized medicines, to date these data
have not been fully explored to improve the effectiveness and
efficiency of drug discovery. Second, modern target-based drug
discovery is characterized as a one-drug-one-gene paradigm, and
has been of limited success in attacking complex diseases. Third,
phenotypic screens and cell-based assays generate a large number
of active compounds relevant to disease treatment, but give few
hints as to what their molecular targets are [6–9]. As a result of
these shortcomings, the cost to launch a new drug is typically more
than US$1 billion, and that cost continues to increase, with only
around one-third of drugs in phase III clinical trials reaching the
market. The emerging field of systems pharmacology is addressing
these shortcomings and beginning to change the way we think
about drug action in multigenic, complex diseases [10–15].
As illustrated in Figure 1, a drug commonly not only interacts
with its intended molecular target (on-target) but also binds to and
affects other targets (off-targets) that are often unknown [16]. Each
drug–target interaction modifies the conformational dynamics of
the target structure and results in the alternation of the functional
states (e.g., activation versus inhibition). Consequently, the
changing conformational and functional states of both on-targets
and off-targets directly or indirectly affects other molecular
components and their interactions through the interplay of
complex signal transduction, gene regulation, and metabolic
networks that collectively mediate the system-level response to
the drug, leading to either therapeutic or adverse effects [10]. A
variety of genetic, epigenetic, and environmental factors define the
initial pathophysiological state of the molecular components and
their interactions, which then dynamically evolve when perturbed
by a drug. Stated another way, both target- and non-target
associated genetic and/or epigenetic alternations could impact the
drug response. In addition to inherited genetic and/or epigenetic
factors, cellular, tissue, and organism environments may have
significant effects on drug efficacy and side effects [17–21]. For
example, tumor–stromal interactions play key roles in anticancer
drug sensitivity [22].
The underlying hierarchical organization of living organisms
makes it essential to model drug actions from DNA to gene, to
protein and its molecular ensemble, to cell, to tissue, to organ, to
whole organism, and to population. Data-driven, network-based
association studies and physical- or mathematical-based multiscale
modeling are two pillars of the existing paradigm of systems
pharmacology. Network-based association studies provide a
promising avenue to realize personalized medicine. The
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reconstruction and analysis of genome-scale molecular interaction
networks, including protein–protein interactions; protein–nucleic
acid interactions; epistasis interactions, as found in signal
transduction; gene regulation; and metabolic networks, have
emerged as a powerful framework to integrate heterogeneous
DNA variation and omics data in associating genotypes with
phenotypes under various environmental and drug-induced
conditions [16]. By taking advantage of the progress in network
and systems biology, mechanism-based multiscale modeling that
spans different temporal and spatial scales has already been able to
predict genotype-phenotype associations in a whole cell model of
Mycoplasma genitalium [23] and quantitatively simulate drug actions
at the organism level [24].
However, several challenges remain in the application of
systems pharmacology. First, data-driven network-based associa-
tion studies primarily rely on sophisticated statistical techniques.
Although great efforts have been made to address the n%p
problem, where the number of observations n is much smaller than
the number of variables or parameters p, the power of these
statistics-based techniques remains limited if sample sizes are
small. The ‘‘causal’’ relationships inferred from these methods are
simply mathematical correlations. They may not provide biolog-
ical insight into the underlying molecular mechanisms that enable
the development of actionable models for understanding the drug-
response phenotype. Second, the existing paradigm of multiscale
modeling is to isolate subsystems (or parameters) from a phenotype
space. These subsystems are first studied independently and then
combined to infer their synergistic behavior. It is noted that the
subsystem itself can be considered as a phenotype. Thus, this
isolation/combination process could be multilevel and recursive.
However, current organism-level physiological models are often
too complex to be supported by existing data and computational
power. The mathematical model is often nonidentifiable; that is,
there is not a unique parameter set to explain the experimental
observations [25]. On the other hand, physical models are often
too computationally intensive to readily model the global behavior
of the physiological system. Fundamentally, isolated parameter
space may be not sufficient to ‘‘identify and elucidate the guiding
principles of control and communication defining the behavior of
an organism’’ [11]. Such a guiding principle is fundamental to
reliably predict human behavior by scaling up animal models.
Third, the enormous investment in molecular libraries and target-,
cell-, and organism-based high-throughput compound screening
has generated a massive amount of chemical genomics data [26–
28]. There is no doubt that these data are invaluable in
understanding how drugs work at the molecular, cellular, and
organismal levels. However, this arguably most important dataset
for systems pharmacology has not been fully incorporated into
either the network-based association studies or multiscale model-
ing frameworks, partly due to a lack of computational tools to map
bioactive chemical space to its global target and pharmacological
space. Lastly, it has been recognized that one of the critical hurdles
in multiomics data integration and multiscale modeling is the lack
of a common language and standard to annotate, exchange, reuse,
and update computational models [29–31]. Due to the dynamic,
complex, and multiscale nature of datasets and computational
models needed to simulate a drug response under diverse genetic,
epigenetic, and environmental conditions, an open and reusable
conceptual framework that is able to link multilevel biological
concepts and relationships is needed to realize the promise of
community-driven predictive modeling of human physiology and
pathology [32–35].
Although macromolecular structure is at the foundation of any
molecular interaction, adding the structural and associated
energetics and dynamics of the interplay between drugs, biomo-
lecular targets, genetic and epigenetic variations, and environ-
mental factors has not been fully exploited in systems pharmacol-
ogy to date. A global three-dimensional macromolecular structure
view of the biological system under study may offer new insights to
address the aforementioned challenges. Stated more explicitly, a
mechanistic understanding of how individual molecular compo-
nents work together in a system and how the molecular
interactions are affected and adapted to genetic and epigenetic
variants and environmental perturbations requires knowledge of
the underlying molecular structures and their conformational
dynamics [36]. The information derived from the atomic details of
molecular interactions, in principle, will enhance the power of
statistical inference in data-driven systems biology and alleviate the
current inability to fully characterize parameter space in
mathematical modeling, revealing the guiding principles of
systematic control and communication. Moreover, as a bridge to
connect chemical and genomics space, macromolecular structure
will allow us to link drugs, targets, and biological pathways,
thereby providing a common framework to correlate molecular
interactions with cellular functions. Leveraging the vast investment in
chemical genomics, functional genomics, structural genomics, and structure-
based drug discovery, together with efforts in systems pharmacology, may open a
new door to developing personalized medicines for complex diseases. Thus,
here we advocate and then justify a new paradigm of structural
systems pharmacology. Structural systems pharmacology will
model, on a genome scale, the energetic and dynamic modifica-
tions of macromolecules (proteins, RNA, DNA) by drugs. The
modeling accounts for genetic/epigenetic and environmental
factors as well as the subsequent collective effects on the
information flow in biological systems.
Some advances have been made in incorporating macromolec-
ular structure modeling into systems pharmacology. We review
them in this article. We demonstrate that integrative modeling of
drug action—from the structural and energetic basis of genome-
wide molecular interactions to the clinical outcomes at the
organism level—provides new insights into both therapeutic
effects and side effects while taking into account genetic
differences. In terms of scope, we first propose a hybrid modeling
approach to integrate mechanism-based multiscale modeling and
Figure 1. A network view of drug action. Dark blue lines represent
drug–target interactions. Green arrows are protein–protein interactions
or biological reaction pathways. Yellow nodes represent genes affected
by genetic variation. These variations will impact drug action by
changing the information flow of drug–target interactions in the
biological network, even when these genes are not themselves the
direct drug targets.
doi:10.1371/journal.pcbi.1003554.g001
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simulation with a data-driven systems biology approach and
suggest that macromolecular structure is an essential component to
glue diverse technologies together into a unified framework. We
demonstrate the potential of macromolecular structures in
enhancing the capability of systems biology through enriching
the connectivity of context-specific biological networks and
resolving non-identifiable parameter space during network simu-
lation. Then we focus on three aspects of structural systems
pharmacology that link genetic events and drug–target interac-
tions to the drug response phenotype. First, we focus on traditional
pharmacodynamics, now in the context of structural systems
pharmacology. Second, and in a similar fashion, we focus on
traditional pharmacokinetics in the context of structural systems
pharmacology. Third, we explore the role of structural systems
pharmacology to enhance the power of pharmacogenomics and
GWAS. Thus, this review complements several recent reviews that
focus on a network view of systems pharmacology and its
connection to phenotype [10–15]. Physical-based multiscale
modeling will not be covered in detail, since this is presented
elsewhere [37–40]. Ultimately, we argue, structural systems
pharmacology should be incorporated into the modeling and
simulation of macromolecular ensembles, tissues, and organisms.
Structural Systems Pharmacology—Structure-
Enabled Integrative Modeling of Drug Action
As stated in the introduction, several challenges remain in
systems pharmacology, limiting the ability to predictively model
complex drug action under the influence of diverse genetic,
epigenetic, and environmental factors. To address these challeng-
es, we suggest an integrative structural systems pharmacology
approach to understanding and predicting individual- and
context-specific drug response phenotypes. In this proposed
modeling framework, macromolecular structure is an indispens-
able component to link chemical space to genomic space, to
associate genotypes with phenotypes, and to account for the
environmental impact on biological systems. To demonstrate the
proposed model, we use the predictive modeling of drug-induced
arrhythmia as an example (Figure 2). Drug-induced arrhythmia is
a potentially life-threatening side effect that is a major concern in
clinical trials. QT interval prolongation that can be measured by
electrocardiogram (ECG) waves has been widely accepted as a
biomarker for arrhythmia. Both multiscale physical and mathe-
matical models [41–42] and network-based predictive models [43]
have been developed to predict QT interval prolongation with the
aim of predicting the drug side effect of arrhythmia at an early
stage (blue-colored box in Figure 2). However, several key
components are missing in these models. As a result, their
prediction power is limited. Given a new or existing drug, we at
least need to address the following issues in order to predict
whether or not the drug may induce arrhythmia under a specific
physiological context for a specific individual (Figure 2):
(1) Identification of genome-wide drug–target interactions. The
QT interval prolongation involves not only multiple ion
channels (e.g., hERG, Kv7.1, Nav1.5, and Cav1.2) but also
multiple other genes that are functionally associated with the
ion channel [43]. In addition, the interaction of a drug with
metabolizing enzymes and regulatory genes may alter the
concentrations of proteins that play roles in arrhythmia and
the pharmacokinetic profile of the drug molecule.
(2) Conformational dynamics and energetics of multiple ion
channels under drug and genetic perturbation. The dynamic
change of ion channel conformations (open and closed) during
gating is the primary determinant of the membrane current
during the action potential. Both drug binding and unbinding
kinetics, as well as amino acid mutations, may impact the
conformational change of the ion channel, leading to the
change of action potential. The events of conformational
dynamics can be modeled by Molecular Dynamics (MD)
simulation. As genome-scale MD simulation is not feasible at
this time, evolutionary and functional constraints that could
be derived from sequencing and multiple omics data will be
an invaluable asset to significantly reduce the conformational
sampling space of MD simulation [44].
(3) Determination of the in vivo concentrations of relevant drugs
and metabolites (e.g., ebastine [45]) that may affect the
activity of ion channels. In principle, this could be achieved
using a whole-body physiologically based pharmacokinetics
(PBPK) model that incorporates tissue-specific, genome-scale
metabolic models. However, to date, little attention has been
paid to adjusting PBPK models using information from
genome-wide drug–target interactions.
(4) Identification of individual- and context-specific parameter
spaces for PBPK and systems biology models. To predict
individual- and context-specific (e.g., normal tissue versus
inflamed tissue) drug responses, it is critical to define
molecular states, network architectures, and dynamic param-
eters at the molecular level under the physiological conditions
that exist during drug treatment. Although a vast amount of
GWAS and multiple types of omics data provide abundant
opportunities for this purpose, these data have not been fully
explored to define biological networks at molecular resolution.
(5) Most importantly, it is necessary to integrate the above
information into a coherent computational model across
temporal and spatial scales. As these tasks traditionally span
multiple disciplines and require different techniques, such as
statistical machine learning [46], MD simulation, Ordinary
Differential Equation (ODE)-based kinetics simulation, con-
straint-based modeling, discrete logic models, etc., they may
need to be implemented as independent functional modules
and subsequently assembled into a complete framework.
Consequently, these functional modules need clearly defined
interfaces and metadata for bi-directional communication.
For example, the PBPK model determines the fate of drug
molecules. In turn, drug–target interactions may regulate the
expression level of CYP450 (as detailed later), thus altering the
parameter space of the PBPK model. It has been suggested
that ontology-driven, rule-based modeling may facilitate the
integrative modeling of drug actions [11]. The integration of
rule-based semantic modeling and Bayesian statistical mod-
eling [47–49], which can establish cause–effect relationships
across temporal and spatial scales, could be a useful tool in
combining diverse techniques and multiple sequencing,
molecular, and omics data. Such a scheme is depicted in
Figure 3. It combines information and biological knowledge
from DNA variants and their associated genes; drug–target
interactions; protein conformational states; biological path-
ways; cellular networks, such as protein–protein interaction
networks; molecular phenotypes, such as gene expression
profiles; and different organism phenotypes. Using these
individualized drug response phenotypes, the probability of
causal mutations, involved targets, conformational states,
molecular complexes or functional modules, and biological
pathways and their links can be established by a priori
knowledge from mechanism-based modeling or estimated
using a Bayesian statistical framework.
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Although we use the arrhythmia example for illustrative
purposes, the framework described in Figure 2 should be
generalizable for the understanding and prediction of drug response
phenotypes. As detailed in the remaining text, we will show that
macromolecular structures play critical roles in reconstructing
genome-scale, high-resolution molecular interaction models, simu-
lating the conformational dynamics of drug–target complexes,
enabling context-specific pharmacokinetics modeling, resolving
nonidentifiable parameters in mathematical modeling, and enhanc-
ing the predictive power of network-based association studies. Thus,
the structure-enabled integrative modeling of drug actions may
facilitate transforming conventional drug discovery process to a new
paradigm based on systems pharmacology.
Molecular Resolution of the Biological Network
and Its Parameter Space
Reconstruction of individual- and context-specific genome-scale
biological networks (e.g., drug–target, protein–protein interaction
(PPI), metabolism, gene regulation, and signal transduction) is the
foundation of systems pharmacology. Concurrently, protein
structure-based PPI networks [50–55] have already made signif-
icant contributions to reliably expanding genome-scale PPIs [51–
52], understanding the molecular mechanism of signal transduc-
tion [56–57], revealing the evolutionary origin of pathogen–host
interactions [58], elucidating the molecular basis of disease
mutations [59], and designing novel molecular therapeutics to
target the network, PPI interfaces, and allosteric modulation, as
summarized by Duren-Frigola et al. [60].
When kinetic parameters are lacking, constraint-based Flux
Balance Analysis (FBA) presents an alternative approach to
compute the phenotypic properties of whole cells, especially
genome-scale metabolic networks [61]. New biological insights
have been gained when incorporating protein structural informa-
tion into metabolic network modeling of bacteria, which cannot be
achieved by FBA alone [62–63]. For example, structure-based
reconstruction of a genome-wide metabolic network makes it
possible to determine bacteria growth in response to temperature
Figure 2. A structure-enabled integrative framework to model drug action. Given a set of inputs—a new or existing drug, known bioactive
chemical space, the whole human proteome, an individual’s genotypic data, and context-specific phenotypic data—it is possible, in principle, to
construct a structure-enabled integrative model of drug action. Such a model comprises multiple integrated functional modules (rounded boxes) that
span multiple levels of biological organization and can be used to infer drug-induced arrhythmia. Solid and open arrows indicate current workflows
and missing links, respectively. Blue boxes represent two existing methods: multiscale ventricular electrophysiological modeling [41–42] and protein–
protein interaction (PPI) network-based predictive modeling [43] for the prediction of drug-induced arrhythmia represented as a pseudo
electrocardiography (ECG). The other boxes represent functional modules that are critically important but have not been fully developed or
incorporated into the modeling process.
doi:10.1371/journal.pcbi.1003554.g002
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changes [64]. This opens a new door to understanding the impact
of the environment on drug action. It is noted that when protein
structures are used, they are often treated as a single chain or as
simply forming binary interactions during network analysis. In
reality, under physiological conditions, proteins perform their
functions through biological assemblies that may consist of
multiple proteins. In a recent study, the 3-D structure of biological
assemblies has been explicitly considered in the context of the
genome-scale metabolic network. Novel drug targets and thera-
peutics are expected to be identified through such an integrative
modeling strategy [65]. Beyond microorganisms, the first recon-
struction of a genome-scale human metabolic network (Recon-1)
by Duarte et al. provided the foundation for applying FBA to
complex disease modeling [66]. By taking advantage of the rapidly
increasing omics data, new methods have been developed to
model cell-specific [67], tissue-specific [68–69], and context-
specific [70–71] human metabolic networks.
Several recent efforts have made progress in reconstructing
genome-scale high-resolution protein–chemical interaction models
[72–76]. As shown in Figure 4A, the targets identified from
chemical genomics and functional genomics data analysis mainly
include existing known drug targets and their homologs, which
only cover a small portion (,8%) of the human genome [77–95].
A large number of proteins whose cognate or designed ligands are
less characterized (or unknown) or who have low-affinity bindings
to drugs are very likely to be important or even critical to
pathophysiological processes under consideration [16]. The target
space can be significantly extended to ,50% of human genes
using structural genomics data [96]. As illustrated in Figure 4B,
when integrating chemical genomics data analysis and molecular
modeling on a structural genome scale, it is possible not only to
greatly extend the existing target space to ,50% of human and
pathogen genomes (a five to 50 times increase over existing
targets), but also to construct genome-wide high-resolution
protein–chemical interaction models for millions of bioactive
compounds [72,97]. Although it remains a challenge to accurately
determine, under physiological conditions, the binding affinity and
binding/unbinding kinetics of these interaction models, these
models provide a basis to simulate the conformational dynamics of
protein targets perturbed by a drug (see details in next sections)
[44,98]. Consequently, the physiological drug response (therapeu-
tic effect or side effect) can be predicted by mapping the
conformational states of drug targets into biological pathways
and networks [44,98]. We expect that the integration of chemical
genomics, structural genomics, and functional genomics will
significantly enhance the capability of systems pharmacology for
molecular target identification of bioactive compounds, drug
repurposing, polypharmacological drug design, and side effect
prediction.
In the context of personalized medicine in the treatment of
complex diseases, a critically important but less-addressed problem
is the need to reconstruct genome-scale, structure-based gene
regulatory networks. In the major groove of DNA, every base pair
has a unique hydrogen-bonding signature, and the ‘‘direct
readout’’ mechanism, in which the formation of a series of amino
acid base-specific hydrogen bonds contributes to the protein-DNA
binding specificity, has been commonly accepted [99]. Recently,
Rohs et al. found that the binding of arginine residues to narrow
minor grooves is a widely used mode for protein–DNA recognition
[100–101]. Differing from the ‘‘direct readout’’ mechanism, their
findings indicate that the minor groove can also provide
information, such as local variations in DNA shape and
electrostatic potential for protein–DNA recognition, and offer
new insights into the structural and energetic origins of protein–
DNA binding specificity. These studies highlight the importance of
the role of macromolecular structures in understanding gene
regulation.
The reconstruction of the biological network is only the first step
in understanding the dynamic and stochastic nature of cellular
processes [102]. +When the network topology and kinetic
parameters are defined, time-dependent deterministic functions,
including Ordinary Differential Equations (ODEs) and Partial
Differential Equations (PDEs) [103], are commonly employed to
analyze the dynamics of signaling and metabolic pathways upon
drug treatment [104]. For instance, ODEs have been successfully
applied to investigate the effects of multitarget inhibition [105–
106], to search for optimal target combinations for safe and
effective anti-inflammation therapy [107], and to predict the
network response to target inhibition [108]. PDEs can be used to
model the concentration change of each component as a function
of both time and space [103]. Such a technique is important in
determining the effective concentration of a drug when it reaches
its targets and off-targets in an essentially nonlinear, non-
equilibrium cellular and microenvironment. Stochasticity is one
of the fundamental properties of cellular processes [102].
Moreover, in vivo drug action involves a series of stochastic
Figure 3. Hierarchical cause-effect semantic modeling to
understand and predict drug action across temporal and
spatial scales by using diverse techniques and integrating
multiple sequencing, molecular, and omics data. Arrowed edges
represent cause-effect relationships between biological entities: genetic
variation, ligand (allosteric or orthosteric), drug target, conformational
state of the drug target, biological pathway, molecular phenotypes
from multiple omics data, integrated biological network, and organism
phenotype (e.g., disease). The thickness of the arrow indicates the
degree of probability. And the + and 2 signs represent positive (or
activated) and negative (or inhibited) regulation, respectively. For
example, an allosteric ligand may interact with target 1 to induce its
active conformation that positively regulates pathway 1. The positively
regulated pathway 1 can be derived from an observed molecular
phenotype 1 (e.g., gene expression profile). A context-specific biological
network can be inferred by integrating multiple molecular phenotypes
and be used to understand and predict an organismal phenotype.
doi:10.1371/journal.pcbi.1003554.g003
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processes such as prodrug transport and efflux [109]. Thus,
stochastic models will be important tools in modeling drug action
[110].
However, dynamic modeling is hampered by the lack of reliable
kinetic parameters. In many cases, the kinetic parameters for
enzyme reactions can be estimated from protein structures [111].
The computational techniques required are dependent on the
reaction mechanism. Quantum Mechanics (QM) or Quantum
Mechanics/Molecular Mechanics (QM/MM) is needed if bond-
breaking is the rate-limiting step. Whereas, Brownian dynamics is
more efficient if the reaction is fast and the diffusion rate is the
determinant. Nevertheless, these computational techniques are
time-consuming and cannot be easily extended to a genome scale.
It has been proposed that the electrostatic potential in the active
site determines not only the stability of transition states [112] but
also the diffusion association rate [113]. Thus, it is proposed that
the comparison of the Molecular Interaction Field (MIF),
including the electrostatic potentials and other physical charac-
teristics of structurally similar proteins, may assist in the estimation
of the kinetic parameters [114]. A similar strategy has been applied
to predict the association/disassociation rate of protein–protein
interactions [115–117], which are essential for the dynamic
modeling of signal transduction pathways. Furthermore, it is
possible to extend the scope of MIF to a structural proteome scale
for structurally unrelated proteins by analyzing and comparing
the evolutionary, dynamical, physiochemical, geometric, and
Figure 4. Reconstruction of genome-wide, high-resolution protein–chemical interaction networks. (A) Distribution of existing drug
targets, PDB structures, and homology models in the human genome. (B) A schema to reconstruct 3-D drug–target interaction networks by
integrating chemical genomics, structural genomics, and functional genomics. Novel drug off-targets could be identified by using the drug–target
interaction models from chemical genomics analysis, and followed by searching for entire human or pathogen structural genome. In addition to
sequence and global structural comparison, ligand binding site comparison is a valuable method, as it can identify binding promiscuity across fold
space [119–121,231–238]. After putative off-targets have been identified from structural genomics analysis, sophisticated molecular modeling
techniques such as protein-ligand docking and Molecular Dynamics (MD) simulation can be applied to determine high-resolution interaction models
and their binding affinity and conformational space. To correlate drug–target interactions with their physiological response, the conformational state
of the drug–-target complex can be mapped to biological pathways, integrated networks, and physiological models. Several examples are shown in
the figure. Semantic-based modeling is able to establish cause-effect from drug to target to pathways and, ultimately, to clinical outcomes [98].
Biological pathway analysis will provide the mechanistic understanding of information flow caused by drug modulation [44]. Critical components and
interactions involved in drug modulation can be identified through integrated protein–protein interaction (PPI) network analysis [212]. Here, blue and
green nodes represent drug targets and genes with observable changes, respectively. The target inhibition or activation along with genetic
perturbations can be simulated using reconstructed physiological models [71]. In turn, the information from pathway and network analysis can be
used to verify or falsify the drug–target interaction models and to constrain their conformational space.
doi:10.1371/journal.pcbi.1003554.g004
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transition-state binding properties of the binding interfaces [118–
122]. The use of estimated kinetics parameters is particularly
promising when coupled with a kinetic hybrid model [123]. In
these models, detailed rate equations are only used to describe
essential enzymes. Simplified and approximate rate equations are
applied to the majority of enzymes. A recent study has shown that
37% of enzymes in Escherichia coli are promiscuous and evolution-
arily retained and catalyze 65% of known metabolic reactions
[124]. With higher catalytic capability, specific enzymes tend to be
essential and more frequently coupled with gene regulation than
promiscuous enzymes. This finding provides additional support for
the structure-based hybrid model. It is noted that the kinetic
parameters are often experimentally measured under three-
dimensional conditions, which do not reflect the two-dimensional
dynamic processes occurring when a drug binds to a receptor. Wu
et al. presented a theoretical multiscale simulation approach that
converts three-dimensional affinities to two dimensions, account-
ing directly for the structure and dynamics of the membrane-
bound molecules [125]. In summary, multiscale mathematical
modeling and network-based association studies in systems
pharmacology will benefit from the information derived from
macromolecular structures in terms of the identification of reliable
network connectivity as well as the enrichment of individual- and
context-specific kinetic parameters.
Pharmacodynamics in the Era of Structural Systems
Pharmacology
A major focus of pharmacodynamics is to quantitatively
understand drug–target interactions and their effects on the whole
organism. It is clear that drug action cannot be fully understood by
a conventional one-drug-one-target paradigm. A systematic view
of all proteome drug–target interactions is often necessary [16]. A
drug molecule may act more than to inhibit or activate a target in
a binary manner. Recent studies in biased agonism (or biased
signaling, functional selectivity) [126] and partial agonism add a
new dimension to understanding pharmacodynamics. For exam-
ple, it has been recognized that a G-protein coupled receptor
(GPCRs) pleiotropically regulates multiple signaling pathways. An
endogenous or designed agonist for a GPCR may selectively
activate one of its regulated pathways, leading to therapeutic
efficacy or, alternatively, to unwanted side effects. At the
molecular level, biased agonism originates from the selection of
specific conformational states of the target protein, which are
dynamically coupled with ligand binding. Fundamentally, the
molecular mechanism of biased agonism may be similar to that of
partial agonism observed in nuclear receptors (NRs). The
transcriptional activity modulated by NR agonists is not dependent
on the binding affinity but rather the ensemble of both protein
conformations and ligand orientations [127–128]. Moreover,
allosteric interaction can shift the conformational ensembles,
thereby modulating the activity of agonist binding [36].
These findings provide both new opportunities and impose
challenges in linking in vitro drug binding with associated in vivo
activity. In addition to identifying proteome-wide drug binding
promiscuity and specificity, it is necessary to sample the
conformational ensemble associated with these drug–target
interactions and to link their conformational state with biological
pathways. Although a number of state-of-the-art computational
techniques (e.g., those reviewed in [16] and Figure 4) are able to
predict drug binding cross-reactivity, few of them provide a high-
resolution landscape for the complete conformational space of
drug–target interactions. State-of-the-art methods accounting for
conformational flexibility are not capable of mapping the
conformational ensembles to the signaling pathways that they
modulate [129]. New concepts and techniques are needed to
include the influence of protein dynamics on functional activity of
drug binding in the context of biological networks.
At the molecular level, conventional single-target, single-state
virtual screening and quantitative structure-activity relationships
(QSAR) should be extended to a multitarget, multiconformation
model. A wide array of experimental techniques, such as
fluorescence spectroscopy [130], plasmon waveguide resonance
spectroscopy [131], bioluminescence resonance energy transfer
[132], circular dichroism [133], X-ray crystallography [134], site-
directed mutagenesis [135], and 19F-NMR spectroscopy [136],
have been developed to determine active conformations associated
with biased and partial agonism. These data provide a foundation
for developing multistate models of pharmacodynamics. Structure-
based molecular modeling may play a critical role in understand-
ing the biased signaling. For example, dynamic protein-ligand
homology modeling coupled with site-directed mutagenesis data is
used to determine the dimerization and activation models for
GPCRs [137–138].
In the context of personalized medicine, the functional selectivity
of drug binding can be modulated by mutations in the protein
target, which directly impact orthosteric or allosteric interactions.
Thus, it is important to assess the importance of the mutation on the
energetics and dynamics of proteome-scale drug–target interactions.
Protein structure may provide critical insights into how the
mutation alters the drug response. The genetic predisposition to
adverse drug reactions (ADR) can be rationalized through the
atomic details of the interaction between the drug and its potential
off-target using structural modeling. For example, Li et al. have
discovered that an R41Q mutation in human cytosolic sialidase
(HsNEU2), which is predisposed in a small portion of the Asian
population, links ADRs to oseltamivir (Tamiflu) [139]. In addition
to mutations that directly involve drug binding, the mutations that
disrupt allosteric interactions are some of the major determinants of
disease but have been little studied [140]. Several structure-based
techniques have been developed to predict the effect of mutations
on allosteric regulation. They include correlated mutation analysis
[141–146], the detection of pairwise dynamic [147–148] or
energetic coupling [149] between residues, and analysis of the
global topology of protein structures [150–151]. These methods
may eventually contribute to the design of allosteric drugs [36,152].
Dynamic simulation of drug unbinding kinetics is another area
that may significantly impact personalized medicine. Drug–target
interactions in vivo are different from those in vitro. In target or cell-
based assays, the concentrations of both drug and target are fixed
and the binding affinity is measured by thermodynamic equilibrium
constants such as IC50 values, which reflect binding potency.
However, in a living organism, the concentration of the drug, the
target, and the other molecules constantly changes with time, rarely
reaching equilibrium. Thus, the drug binding affinity is not an
appropriate indicator of drug potency in vivo [153]. An increasing
body of evidence suggests that drug efficacy correlates more strongly
with drug–target residence time than with binding affinity [154–
157]. Long residence time can lead to sustained pharmacological
effect and may also alleviate off-target toxicity. The residence time
of a drug on its target can be greatly influenced by conformational
adaptation [158]. Recent studies suggest that the in vivo duration of
drug efficacy not only depends on macroscopic pharmacokinetic
properties like plasma half-life and the time needed to equilibrate
between the plasma and the effect compartments, but is also
influenced by long-lasting target binding and rebinding [159].
Experimental approaches to studying drug binding and
unbinding to proteins have limitations in temporal and spatial
resolution. It was reported recently that a computational network
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analysis combined with explicit water MD simulations of the
unbinding of small inhibitors from the enzyme FK506 Binding
Protein (FKBP) provided a clear picture of the free energy
landscape (both thermodynamics and kinetics) of ligand dissoci-
ation [160]. The dissociation kinetics were characterized as a
simple (i.e., single-exponential) time dependence with multiple
dissociation pathways. A computational methodology using
trajectory data from multiple Brownian dynamics simulations of
ligand diffusion has been developed for characterizing the kinetics
of drug–receptor interactions in terms of the encounter complex
[161]. A computational approach named metadynamics has been
used both for reconstructing the free energy and for accelerating
rare events in systems described by complex Hamiltonians, at the
classical or at the quantum level [162]. All-atom metadynamics
simulations of a peptide substrate interacting with wild-type HIV-1
protease in explicit solvent rendered accurate calculations of
binding affinity and kinetics constant compared to the experi-
mental data [163].
Ultimately, drug–target interactions and genetic events should
be studied in the context of biological networks. Existing biological
network analysis is conformationally stateless. Thus, these
networks are not sufficient to model the influence of protein
dynamics on the drug response phenotype. The integrative
modeling depicted in Figures 2 and 3 provides a possible solution
to incorporating conformational dynamics into network modeling.
It is worth mentioning that this integrative modeling framework
could also be a powerful tool in studying the pharmacodynamics of
drug–drug interactions. Due to the robust nature of biological
systems, drug combinations are often necessary and proven to be
successful in treating complex diseases and combating drug
resistance [164–165]. However, the Adverse Drug Reaction
(ADR) resulting from drug–drug interaction is a serious problem
in developing combination therapies. In addition to the pharma-
cokinetics (see next section), the pharmacodynamics of the drug–
drug interaction may play a critical role in the ADR [166].
Existing state-of-the-art methods for the prediction of drug–drug
interactions are data-driven, which mainly establish statistical
association from empirical observations but provide little infor-
mation on the mechanism of drug–drug interaction. Thus, they
may not be sufficient for the predictive modeling of drug–drug
interactions during the early stages of drug development [167–
168]. Using the proposed integrative modeling framework, it may
be possible to predict drug–drug interactions de novo.
Pharmacokinetics in the Era of Structural Systems
Pharmacology
The Absorption, Distribution, Metabolism, and Excretion
(ADME) properties of a drug, i.e., absorption and distribution to
its target(s), detoxification by metabolism and excretion of the drug
from the human body, are the primary concerns of pharmaco-
kinetics. At the molecular level, ADME properties are strongly
influenced by the abundance and activity of transporters and
metabolizing enzymes such as CYP450, UDP-glucuronosyltrans-
ferases, sulfotransferases, N-acetyltransferases, glutathione S-trans-
ferases, and methyltransferases. Much effort has gone into
developing computational methods for in silico prediction of
ADME properties. These methods initially only addressed the
small drug molecule. Based on chemical structures, quantitative
structure-activity relationship (QSAR)-based approaches have
been extensively used to correlate the physiochemical properties
of lead molecules with their ADME profiles [169–170]. Shifting
from the ligand to the receptor, structure-based methods have
been developed which leverage the ever-increasing number of 3-D
structures of ADME related proteins. Similarity searches and
traditional pharmacophore approaches are enhanced by more
advanced molecular descriptors and 3-D pharmacophores that
encode the details of ligand-target binding [171]. Dynamic
properties of ligand-target binding could be incorporated into
the pharmacophore with conformational sampling techniques.
Protein-ligand docking based on virtual screening for millions of
compounds can now be accomplished with ease [172]. However,
applying molecular docking to ADME related proteins is
complicated by the existence of large and flexible binding cavities
in CYP450 and phase II metabolizing enzymes, which can
accommodate more than one ligand [172]. Consequently, the
correlation between the docking score obtained for the best poses
with experimentally determined binding free energies is usually
poor. Nevertheless, in a recent study, Schlessinger et al. used a
homology model of a norepinephrine transporter and molecular
docking to successfully predict the prescription drugs which
specifically bind to it [173]. With the availability of data from
chemical genomics and high-throughput screening [28,174], the
combination of multiple flexible docking tools with chemoinfor-
matics may boost the performance of structure-based virtual
screening [175]. Although more accurate in deriving binding free
energy, a more rigorous thermodynamic approach is unfortunately
more computationally demanding and not applicable to large-
scale virtual screening. Besides molecular docking based virtual
screening or molecular dynamics simulation, quantum mechanical
and hybrid quantum mechanical/molecular mechanical (QM/
MM) methods have emerged as powerful tools for modeling
reaction rates of drug metabolism. The whole reaction profile for
benzene hydroxylation by CYP2C9 was studied with such a
hybrid approach; a combined docking-MD-QM calculation was
used to simulate the activation energy of CYP3A4 [176]. The
challenge is to extend this technique to a structural proteome scale,
as discussed in the previous sections.
So far, pharmacogenomics prediction of ADME properties has
mainly focused on the genotypic variations and polymorphisms in
metabolizing enzymes—the overall contribution of pharmacoge-
nomics to personalized medicine remains limited [177]. The
pharmacokinetics of a drug is the interplay between the inherent
physiochemical properties of the drug and its physiological
environment. The expression of metabolizing enzymes and
transporters is highly regulated by multiple factors, including
genetic polymorphisms, xenobiotics induction, cytokines, hor-
mones, and pathophysiological states, as well as gender and age of
families [178]. Multi-allelic genetic polymorphisms depend signif-
icantly on ethnicity and imply disparate clinical phenotypes
including ADR, drug efficacy, drug resistance, and dose require-
ment. A mechanistic understanding of these regulators is essential
for the predictive modeling of pharmacokinetics. It is well
established that CYP genes are directly regulated by nuclear
receptors [179]. Multiple genes, such as p53, AP-1, Ras, and APC,
are involved in the regulation of multiple drug-resistance
transporters (ABC transporters) [180]. If a drug itself, or another
drug, interacts with these genes, undesirable pharmacokinetics
profiles or drug–drug interactions may arise. Thus, the pharma-
cokinetics regulatory genes are potential drug off-targets that affect
the fate of drug molecules in vivo. We call them ‘‘pharmacoki-
netics off-targets’’ to distinguish them from those related to
pharmacodynamics. The fact that the activity of direct pharma-
cokinetics regulatory genes can be modified by their upstream
genes adds a new layer of complexity to the problem. Therefore, to
fully understand the molecular mechanisms underlying the
ADME properties of a drug, it is necessary to identify the
pharmacokinetics off-targets as well as the regulatory network of
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pharmacokinetics genes on a proteome scale. Figure 5 shows a
regulatory pathway of CYP3A, whose substrates include several
hundred drugs [181]. LCMT1 is a methyltransferase that
methylates the PP2A catalytic subunit and promotes its functional
association with the PP2A regulatory subunits. PP2A is a major
protein phosphatase that dephosphorylates PRMT1, thus inhib-
iting PRMT1 enzymatic activity. PRMT1 is essential for the PXR
transcription process. PXR dimerises with RXR to induce the
gene expression of CYP3A. It is clear that genetic variations or
drug perturbations on any one of the genes along this pathway
may affect the abundance and activity of CYP3A, thereby leading
to a change in the ADME properties. Using a structure-based off-
target identification pipeline, LCMT1 has been identified as the
off-target of several antibiotics [182], highlighting the potential
power of proteome-scale structural modeling in predicting novel
pharmacokinetics profiles and drug–drug interactions.
Noncoding DNA may play important roles in the regulation of
transporters and metabolizing enzymes. For example, the CYP
family includes 58 pseudogenes that do not encode functional
protein [183]. An increasing body of evidence suggests that
pseudogenes have diverse functions that influence not only their
parent genes but also apparently unrelated genes [184]. For
example, one of the CYP450 genes, CYP2A6, has a pseudogene,
CYP2A7. CYP2A7 may transfer a fragment of DNA to its parent
gene CYP2A6, leading to a change in its sequence. It is observed
that individuals who smoke have a mutated gene CYP2A6*1B that
is converted from a CYP2A7 polymorphism. CYP2A6*1B
stabilizes its mRNA, thereby increasing first its expression level,
then its activity in metabolizing nicotine [185]. The functional
roles of most pseudogenes still remain elusive. Structural systems
biology, as discussed in the next section, may shed new light on the
functional relevance of noncoding DNA in pharmacokinetics.
Drug metabolism is strongly dependent on the physiological
state (e.g., obesity and diabetes) and environment (e.g., gut-
microbiome). The prediction of inter-individual pharmacokinetics
variation requires the coupling of pharmacogenomics and
pharmacometabonomics [186]. In principle, mechanism-based
modeling of drug interactions with transporters and metabolizing
enzymes can be integrated with pharmacogenomics, pharmaco-
metabonomics, and other omics data using the integrative
modeling framework proposed in the previous section. Physiolog-
ically based pharmacokinetics modeling has been developed in the
past four decades. Although it is resource consuming in obtaining
input parameters, progress made in in silico technologies has
greatly facilitated the prediction of oral absorption and hepatic
metabolism as well as mechanistic models of tissue distribution
based on pharmacokinetics models. The bottleneck for physiolog-
ically based pharmacokinetics modeling resides in the limited data
available. As discussed in the previous section, dynamic simula-
tions involving comprehensive metabolic pathways, signaling
pathways, and cell physiology are being studied together with
multiscale modeling at the cellular, organ, and whole-body levels
[187]. The sparse number of available kinetic parameters calls for
more structure-based modeling efforts in order to enable further
multiscale systems pharmacology analysis.
Pharmacogenomics and GWAS in the Era of
Structural Systems Pharmacology
Recent advances in pharmacogenetics and pharmacogenomics
have identified genetic variants in several hundreds genes, notably
drug metabolizing enzymes (e.g., CYP450), transporters, and drug
targets [188]. The knowledge derived from such data has already
resulted in individualized therapy. For example, the appropriate
initial dose of the anticoagulation drug warfarin can be estimated
using a pharmacogenomics algorithm [189]. Similarly, certain
mutations can be used to predict alternative responsiveness to
drugs in cancer therapy [190–194]. Acknowledgment of the
emerging role of pharmacogenomics can be found in the labels of
the Food and Drug Administration (FDA)-approved drugs
montelukast [195] and cetuximab [196] and in FDA-approved
diagnostic tests, for example, the microarray-based Roche
AmpliChip for cytochrome P450 polymorphisms and the Invader
UGT1A1 Molecular Assay for detecting polymorphisms that
increase the risk of neutropenia when using the colon cancer drug
irinotecan [15,197].
In spite of these advances, much more is needed for predictive
modeling of individual drug responses. It is critical to understand
the impact of genetic variation beyond direct drug interactions
with on-targets, off-targets, metabolizing enzymes, and transport-
ers. Many nontarget-associated genetic factors may affect the drug
response phenotype. As shown in Figure 1, if a critical node, edge,
or feedback loop is modified in a drug modulation pathway, the
drug efficacy or side effect profile can change accordingly. One
example is the mutation of K-RAS located downstream of the
EGFR pathway, which causes resistance to the anticancer activity
of EGFR inhibitors [198–199]. In another situation, genes aside
from the drug target may regulate the same biological pathway
where the system-level drug response is the result of their
combinatorial control. The mutation or expression changes of
such genes may enhance or reduce the drug response. The gain- or
loss-of-function of mutations that are associated with drug action
may come from genetic variations in both coding and noncoding
regions. Recently, the 1,000 Genomes Project has identified 38
million single nucleotide polymorphisms (SNPs), 1.4 million short
insertions and deletions, and more than 14,000 larger deletions
from 1,092 individuals belonging to 14 ethnic groups. The
individual-specific, rare, coding variants are located across a broad
array of biological pathways. Moreover, there are hundreds of
functionally annotated, rare, noncoding variants for each individ-
ual [200]. It is expected that these variants will alter the
pharmacokinetics, pharmacodynamics, and responsiveness to drug
therapy [15]. The extremely large, multidimensional datasets from
these studies present an exciting opportunity to expand the
horizon of pharmacogenomics by identifying causal variants and
Figure 5. A proposed pathway that modulates the abundance
and activity of CYP3A. LCMT1 is a potential off-target for antibiotics.
The inhibition of LCMT1 will activate PXR, thereby increasing the
activity of CYP3A.
doi:10.1371/journal.pcbi.1003554.g005
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genes, and predicting pathways likely to be involved in drug
response. The challenge is how to associate these data with a
predicted drug response a priori.
Many disease-associated variants and drug-response cryptic
genetic factors remain uncharacterized; hence, new methods are
urgently needed to annotate DNA variants, their functional roles,
and their associations with drug actions. How to annotate the
functional roles of DNA variants, especially for noncoding
variants, is a challenge because of the diversity of noncoding
functions, the incomplete annotation of regulatory elements, and
unknown mechanisms of regulatory control. Several large-scale
studies have been performed to annotate the noncoding genome
and regulatory elements. These studies integrate the high-
throughput functional genomics and comparative genomics
datasets [3–5] to map the functional noncoding elements on a
genome-wide scale. Variants on these elements can result in the
different regulation of their target genes. For example, studies from
the Encyclopedia of DNA elements (ENCODE) [201] and model
organism Encyclopedia of DNA elements (modENCODE) [202–
204] projects provide comprehensive maps of transcription
binding for select cell lines and DNase maps for many primary
cells and highlight the importance of noncoding DNAs in the
regulation of complex phenotypes. With known functional
elements and motifs, methods have been developed to predict
the effect of newly observed rare and private mutations by
integrating models of sequence motifs, chromatin states, and
expression patterns in model organisms and in cultured human
cells [205–208]. For example, quantitative sequence-activity
models (QSAMs) [209] are trained based on these data in a
massively parallel reporter assay (MPRA) developed to enable
systematic dissection and optimization of transcriptional regulato-
ry elements [208].
Since annotated pharmacogenomics biomarkers are incomplete
and biased, the conventional ‘‘guilt-by-association’’ approach may
not be sufficient to identify novel drug-response genetic markers
[43]. The power of statistical analysis of pharmacogenomics and
GWAS data is often limited by the moderate effect size of samples.
As a result, a number of rare variants could be missed.
Fundamentally, the genotype–phenotype relations established by
statistical or machine learning approaches may be merely
mathematical correlations. Macromolecular structures and their
interactions may provide critical mechanistic insight into the
functional roles of DNA variants and their impact on drug action.
The modeling and analysis of macromolecular structures has
already made significant contributions to our understanding of
how mutations affect the stability, folding, and binding of
macromolecules [210–211]. Several recent structure-based studies
have provided high-resolution pictures for how variants rewire
biological networks through allosteric regulation, protein–protein
interaction (PPI), and protein–nucleic acid interaction (PNI)
[59,140,212–213]. Kowarsch et al. showed that co-evolving
residues can influence each other through allosteric regulation
and are significantly more likely to be disease-associated than
expected by chance [140]. By mapping the mutations on the
structures, Wang et al. found that in-frame mutations are enriched
on the interaction interfaces of proteins associated with the
corresponding diseases and that the disease specificity for different
mutations can be explained by their location within an interface
[59]. Similar findings were observed in David et al.’s work [213]
by combining a database of the 3-D structures of human protein/
protein complexes [214] and the humsavar database of non-
synonymous Single Nucleotide Polymorphisms (nsSNPs) [215].
As shown in Figure 1, proteome-wide drug–target interactions
and genome-wide genetic variants may collectively affect the
functional state of complex biological networks that mediate the
system-level response to the drug, leading to both therapeutic and
adverse effects. Few computational tools are able to model the
collective effects of drug perturbation and genetic variants in the
context of the whole human genome and biological network, which
is essential for the development of personalized medicines. Pathway
analysis such as gene-set enrichment analysis (GSEA) [216] can be
applied to pharmacogenomics data to concentrate the genetic
perturbation along the annotated biological pathways. Another way
to use prior knowledge of gene interrelationships is to incorporate
the information into the association study itself through Bayesian
techniques [217] or by using boosting to prioritize disease networks
[218]. By integrating the atomic details of molecular interactions,
co-evolution information, protein–protein interaction networks,
transcriptional profiles, and pathway enrichment analysis, Xie et al.
developed a structural systems biology approach to identifying the
functional role of DNA variants and causal mutations with an
extremely small sample size [212]. Through this approach, the
driver mutations that confer hypoxia tolerance in Drosophila
melanogaster were identified. Furthermore, the functional roles of
several nsSNPs, which are predominantly involved in allosteric
regulation, protein–protein interaction, and protein–nucleic acid
interaction, were determined [212]. The power of variation-
mediated pathway analysis can be further enhanced by incorpo-
rating other regulatory and signaling network components, such as
microRNA–target interactions, protein–nucleic acid interactions,
and phosphorylation events, etc., and taking advantage of advanced
graph mining algorithms [219–220].
The systematic perturbation of sequence variants can be
introduced into the dynamics simulation of pathways and
genome-scale modeling of biological networks through macromo-
lecular structures. Recently, Cheng et al. developed a computa-
tional framework to integrate missense mutation, protein struc-
tural modeling, and ODE [221]. They introduced the Systemic
Impact Factor (SIF) as a measurement of phenotype changes
resulting from the mutation. SIF is a function of the free energy
change caused by the mutation and systemic control coefficient.
The free energy change in a protein directly leads to the change in
its kinetic parameters. The control coefficient quantifies the
sensitivity of the phenotype readout to the change in kinetic
parameters. They tested their models on two cases: G2-M
transition control in yeast and the human mitogen-activated
protein kinase (MAPK) pathway. The SIF from the simulation is
well correlated with the experimental results. The missense
mutations in this study are mainly associated with protein stability.
In the future, it will be interesting to quantify the systematic
impact of broad types of mutations that modify allosteric
regulation, molecular interaction, and gene expression. Chang et
al. have integrated a reconstructed kidney model with structural
bioinformatics and molecular modeling to predict the side effect
profile of cholesterylester transfer protein (CETP) inhibitors and to
identify genetic risk factors that cause adverse drug reactions [71].
An interesting finding from this study is the synthetic effect of
drug–target interactions and nontarget-associated genetic modifi-
cations. Serious side effects are caused by the combination of the
drug treatment and the genetic alteration but not by either alone.
It is anticipated that the identification of nontarget genetic factors
that affect drug action will have a significant impact on
personalized medicine.
Conclusion
The holistic, adaptive, and evolving nature of biological systems
makes the quest for a simple and elegant mechanistic model to
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explain and predict biological phenomena less than fruitful. At the
same time, the emergence of big data should significantly shift our
approach to biomedical research. Given these data and increased
computer power, useful predictive statistical models are possible.
The question then becomes, how can we discover new knowledge
from these statistical models under conditions that are constantly
changing?
A complex disease state is not static under drug treatment, but
evolves to new states in adapting to the drug-induced environ-
ment. When enough data are collected to describe one disease
state and a successful model can be built, the disease may already
be different from the one used to build the model. In such a
temporal situation, a data-driven model is essentially retrospective
but not prospective. Another major question is how much data are
enough to build an accurate predictive model given the genetic,
epigenetic, and clinical heterogeneity of complex diseases? Will the
model still work if the individual has an unobserved new mutation?
Moreover, genetic and/or epigenetic events and drug actions are
rooted in the fundamental principle of physics and chemistry.
Indifference to the detailed physical and chemical nature of
biological processes in the modeling of big biological data could
eventually hinder scientific advances in biomedicine. Discovery of
new knowledge requires more than just a query of a big reference
table built from data. Macromolecular structure plays an
irreplaceable role in linking the physical and chemical origins of
genetic events and drug action to the systematic response at the
cellular, tissue, and organism levels. Thus, the incorporation of
physiochemical-based macromolecular structure modeling with
data-driven and mathematical-based pharmacodynamics, phar-
macokinetics, pharmacogenomics, and systems pharmacology will
not only enhance the power of modeling a predictive personalized
drug response but will also shed new light on our understanding of
living systems in a broad sense.
One of the barriers in applying macromolecular structure to
pharmacogenomics and systems pharmacology is that the struc-
tural coverage of macromolecules and their complexes has been
limited. Recent progress in both experimental and computational
techniques has dramatically improved the structural coverage of
the human genome. In addition to continuous efforts in structural
genomics [222], breakthroughs in the crystallography of mem-
brane proteins make representative 3-D structures of pharmaceu-
tically important proteins such as G-protein coupled receptors
(GPCR) [223] and transporters available [224–226]. Moreover,
complexes of protein-ligand, protein-protein, and protein-nucleic
acid structures, as found in the Research Collaboratory for
Structural Bioinformatics (RCSB) Protein Data Bank (PDB), are
increasing rapidly in both number and complexity [227]. Using
the increased number of structural templates, and given the
availability of high-performance computing, structure prediction
has become routine for data from next generation sequencing.
Even without structural templates, novel protein folds can be
predicted with increasing accuracy [228]. Using co-evolutionary
information from amino acid residues, high-quality structural
models can now be built for proteins that are not amenable to
conventional homology modeling or other methods of ab initio
prediction [229]. Integrative modeling using different experimen-
tal techniques has contributed significantly in constructing
macromolecular ensembles of unprecedented complexity [230].
Similarly, novel computational techniques have been developed to
predict proteome-scale, 3-D interaction models of protein–protein
interactions from medium to high resolution [50–52,58]. Collec-
tively, these advances provide new opportunities to use macro-
molecular structures in pharmacogenomics and systems pharma-
cology.
References
1. Jones SJ (1995) An update and lessons from whole-genome sequencing projects.
Curr Opin Genet Dev 5: 349–353.
2. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for
transcriptomics. Nat Rev Genet 10: 57–63.
3. Park PJ (2009) ChIP-seq: advantages and challenges of a maturing technology.
Nat Rev Genet 10: 669–680.
4. Meissner A, Gnirke A, Bell GW, Ramsahoye B, Lander ES, et al. (2005)
Reduced representation bisulfite sequencing for comparative high-resolution
DNA methylation analysis. Nucleic Acids Res 33: 5868–5877.
5. Boyle AP, Davis S, Shulha HP, Meltzer P, Margulies EH, et al. (2008) High-
resolution mapping and characterization of open chromatin across the genome.
Cell 132: 311–322.
6. Eggert US (2013) The why and how of phenotypic small-molecule screens. Nat
Chem Biol 9: 206–209.
7. Schenone M, Dancik V, Wagner BK, Clemons PA (2013) Target identification
and mechanism of action in chemical biology and drug discovery. Nat Chem
Biol 9: 232–240.
8. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, et al. (2010)
Chemical genetics of Plasmodium falciparum. Nature 465: 311–315.
9. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, et al. (2010) Thousands of
chemical starting points for antimalarial lead identification. Nature 465: 305–
310.
10. Berger SI, Iyengar R (2009) Network analyses in systems pharmacology.
Bioinformatics 25: 2466–2472.
11. Sorger PK, Allerheiligen SRB, Abernethy DR, Altman RB, Brouwer KLR, et
al. (2011) Quantitative and Systems Pharmacology in the Post-genomic Era:
New Approaches to Discovering Drugs and Understanding Therapeutic
Mechanisms. Ward R, editor. NIH White Paper. Available: http://www.
nigms.nih.gov/Training/Documents/SystemsPharmaWPSorger2011.pdf. Ac-
cessed 7 April 2014.
12. Yang R, Niepel M, Mitchison TK, Sorger PK (2010) Dissecting variability in
responses to cancer chemotherapy through systems pharmacology. Clin
Pharmacol Ther 88: 34–38.
13. Hansen J, Zhao S, Iyengar R (2011) Systems pharmacology of complex
diseases. Annals New York Acad Sci 1245: E1–5.
14. Wist AD, Berger SI, Iyengar R (2009) Systems pharmacology and genome
medicine: a future perspective. Genome Med 1: 11.
15. Zhao S, Iyengar R (2012) Systems pharmacology: network analysis to identify
multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 52: 505–521.
16. Xie L, Kinnings SL, Bourne PE (2012) Novel Computational Approaches to
Polypharmacology as a Means to Define Responses to Individual Drugs. Annu
Rev Pharmacol Toxicol 52: 361–379.
17. Sun Y, Campisi J, Higano C, Beer TM, Porter P, et al. (2012) Treatment-
induced damage to the tumor microenvironment promotes prostate cancer
therapy resistance through WNT16B. Nat Med 18: 1359–1368.
18. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, et al. (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through
HGF secretion. Nature 487: 500–504.
19. Wilson ID (2009) Drugs, bugs, and personalized medicine: pharmacometabo-
nomics enters the ring. Proc Natl Acad Sci U S A 106: 14187–14188.
20. Gutiu IA, Andries A, Mircioiu C, Radulescu F, Georgescu AM, et al. (2010)
Pharmacometabonomics, pharmacogenomics and personalized medicine.
Rom J Intern Med 48: 187–191.
21. Nicholson JK, Wilson ID, Lindon JC (2011) Pharmacometabonomics as an
effector for personalized medicine. Pharmacogenomics 12: 103–111.
22. McMillin DW, Negri JM, Mitsiades CS (2013) The role of tumour-stromal
interactions in modifying drug response: challenges and opportunities. Nat Rev
Drug Discov 12: 217–228.
23. Karr JR, Sanghvi JC, Macklin DN, Gutschow MV, Jacobs JM, et al. (2012) A
whole-cell computational model predicts phenotype from genotype. Cell 150:
389–401.
24. Krauss M, Schaller S, Borchers S, Findeisen R, Lippert J, et al. (2012)
Integrating cellular metabolism into a multiscale whole-body model. PLoS
Comput Biol 8: e1002750.
25. Gutenkunst RN, Waterfall JJ, Casey FP, Brown KS, Myers CR, et al. (2007)
Universally sloppy parameter sensitivities in systems biology models. PLoS
Comput Biol 3: 1871–1878.
26. Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker BA, et al. (2010) An
overview of the PubChem BioAssay resource. Nucleic Acids Res 38: D255–266.
27. Li Q, Cheng T, Wang Y, Bryant SH (2010) PubChem as a public resource for
drug discovery. Drug Discov Today 15: 1052–1057.
28. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. (2012) ChEMBL:
a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40:
D1100–1107.
PLOS Computational Biology | www.ploscompbiol.org 11 May 2014 | Volume 10 | Issue 5 | e1003554
29. Palsson B, Zengler K (2010) The challenges of integrating multi-omic data sets.
Nat Chem Biol 6: 787–789.
30. Joyce AR, Palsson BO (2006) The model organism as a system: integrating
‘omics’ data sets. Nat Rev Mol Cell Biol 7: 198–210.
31. Wiley HS (2011) Integrating multiple types of data for signaling research:
challenges and opportunities. Sci Signal 4: pe9.
32. Derry JM, Mangravite LM, Suver C, Furia MD, Henderson D, et al. (2012)
Developing predictive molecular maps of human disease through community-
based modeling. Nat Genet 44: 127–130.
33. Oku Y (2010) Future perspectives - proposal for Oxford Physiome Project. Adv
Exp Med Biol 669: 57–60.
34. Noble D (2009) Systems biology, the Physiome Project and oriental medicine.
J Physiol Sci 59: 249–251.
35. Hunter PJ, Crampin EJ, Nielsen PM (2008) Bioinformatics, multiscale
modeling and the IUPS Physiome Project. Brief Bioinform 9: 333–343.
36. Nussinov R, Tsai CJ, Csermely P (2011) Allo-network drugs: harnessing
allostery in cellular networks. Trends Pharmacol Sci 32: 686–693.
37. White R, Peng G, Demir S (2009) Multiscale modeling of biomedical,
biological, and behavioral systems (Part 1). IEEE Eng Med Biol Mag 28: 12–
13.
38. White RJ, Peng GC, Demir SS (2009) Multiscale modeling of biomedical,
biological, and behavioral systems (part 2). IEEE Eng Med Biol Mag 28: 8–9.
39. Dada JO, Mendes P (2011) Multi-scale modelling and simulation in systems
biology. Integr Biol (Camb) 3: 86–96.
40. Flores SC, Bernauer J, Shin S, Zhou R, Huang X (2012) Multiscale modeling
of macromolecular biosystems. Brief Bioinform 13: 395–405.
41. Silva JR, Pan H, Wu D, Nekouzadeh A, Decker KF, et al. (2009) A multiscale
model linking ion-channel molecular dynamics and electrostatics to the cardiac
action potential. Proc Natl Acad Sci U S A 106: 11102–11106.
42. Obiol-Pardo C, Gomis-Tena J, Sanz F, Saiz J, Pastor M (2011) A multiscale
simulation system for the prediction of drug-induced cardiotoxicity. J Chem Inf
Model 51: 483–492.
43. Berger SI, Ma’ayan A, Iyengar R (2010) Systems pharmacology of
arrhythmias. Sci Signal 3: ra30.
44. Xie L, Evangelidis T, Xie L, Bourne PE (2011) Drug Discovery Using
Chemical Systems Biology: Weak inhibition of multiple kinases may contribute
to the anti-cancer effect of Nelfinavir. PLoS Comp Biol 7: e1002037.
45. Rico S, Antonijoan R, Barbanoj M (2009) Ebastine in the light of CONGA
recommendations for the development of third-generation antihistamines.
J Asthma Allergy 2: 73–92.
46. Murphy RF (2011) An active role for machine learning in drug development.
Nat Chem Biol 7: 327–330.
47. Chen B, Dong X, Jiao D, Wang H, Zhu Q, et al. (2010) Chem2Bio2RDF: a
semantic framework for linking and data mining chemogenomic and systems
chemical biology data. BMC Bioinformatics 11: 255.
48. Lemons NW, Hu B, Hlavacek WS (2011) Hierarchical graphs for rule-based
modeling of biochemical systems. BMC Bioinformatics 12: 45.
49. Ashby D (2006) Bayesian statistics in medicine: a 25 year review. Stat Med 25:
3589–3631.
50. Tuncbag N, Gursoy A, Nussinov R, Keskin O (2011) Predicting protein-
protein interactions on a proteome scale by matching evolutionary and
structural similarities at interfaces using PRISM. Nature Protocols 6: 1341–
1354.
51. Zhang QC, Petrey D, Garzon JI, Deng L, Honig B (2013) PrePPI: a structure-
informed database of protein-protein interactions. Nucleic Acids Res 41:
D828–833.
52. Zhang QC, Petrey D, Deng L, Qiang L, Shi Y, et al. (2012) Structure-based
prediction of protein-protein interactions on a genome-wide scale. Nature 490:
556–560.
53. Mosca R, Ceol A, Aloy P (2013) Interactome3D: adding structural details to
protein networks. Nat Methods 10: 47–53.
54. Kim PM, Lu LJ, Xia Y, Gerstein MB (2006) Relating three-dimensional
structures to protein networks provides evolutionary insights. Science 314:
1938–1941.
55. Kiel C, Beltrao P, Serrano L (2008) Analyzing protein interaction networks
using structural information. Annu Rev Biochem 77: 415–441.
56. Kuzu G, Keskin O, Gursoy A, Nussinov R (2012) Constructing structural
networks of signaling pathways on the proteome scale. Curr Opin Struct Biol
22: 367–377.
57. Kar G, Keskin O, Nussinov R, Gursoy A (2012) Human proteome-scale
structural modeling of E2-E3 interactions exploiting interface motifs.
J Proteome Res 11: 1196–1207.
58. Franzosa EA, Xia Y (2011) Structural principles within the human-virus
protein-protein interaction network. Proc Natl Acad Sci U S A 108: 10538–
10543.
59. Wang X, Wei X, Thijssen B, Das J, Lipkin SM, et al. (2012) Three-dimensional
reconstruction of protein networks provides insight into human genetic disease.
Nat Biotechnol 30: 159–164.
60. Duran-Frigola M, Mosca R, Aloy P (2013) Structural systems pharmacology:
the role of 3D structures in next-generation drug development. Chem Biol 20:
674–684.
61. Price ND, Reed JL, Palsson BO (2004) Genome-scale models of microbial cells:
evaluating the consequences of constraints. Nat Rev Microbiol 2: 886–897.
62. Shen Y, Liu J, Estiu G, Isin B, Ahn YY, et al. (2010) Blueprint for antimicrobial
hit discovery targeting metabolic networks. Proc Natl Acad Sci U S A 107:
1082–1087.
63. Zhang Y, Thiele I, Weekes D, Li Z, Jaroszewski L, et al. (2009) Three-
dimensional structural view of the central metabolic network of Thermotoga
maritima. Science 325: 1544–1549.
64. Chang RL, Andrews K, Kim D, Li Z, Godzik A, et al. (2013) Structural systems
biology evaluation of metabolic thermotolerance in Escherichia coli. Science
340: 1220–1223.
65. Chang RL, Xie L, Bourne PE, Palsson BO (2013) Antibacterial mechanisms
identified through structural systems pharmacology. BMC Syst Biol 7: 102.
66. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, et al. (2007) Global
reconstruction of the human metabolic network based on genomic and
bibliomic data. Proc Natl Acad Sci U S A 104: 1777–1782.
67. Bordbar A, Lewis NE, Schellenberger J, Palsson BO, Jamshidi N (2010) Insight
into human alveolar macrophage and M. tuberculosis interactions via
metabolic reconstructions. Mol Syst Biol 6: 422.
68. Jerby L, Shlomi T, Ruppin E (2010) Computational reconstruction of tissue-
specific metabolic models: application to human liver metabolism. Mol Syst
Biol 6: 401.
69. Shlomi T, Cabili MN, Herrgard MJ, Palsson BO, Ruppin E (2008) Network-
based prediction of human tissue-specific metabolism. Nat Biotechnol 26:
1003–1010.
70. Becker SA, Palsson BO (2008) Context-specific metabolic networks are
consistent with experiments. PLoS Comput Biol 4: e1000082.
71. Chang RL, Xie L, Xie L, Bourne PE, Palsson B (2010) Drug Off-Target Effects
Predicted Using Structural Analysis in the Context of a Metabolic Network
Model. PLoS Comput Biol 6: e1000938.
72. Ng C, Hauptman R, Zhang YL, Bourne PE, Xie L (2014) Anti-infectious drug
repurposing using an integrated chemical genomics and structural systems
biology approach. Pac Symp Biocomput 19: 136–147.
73. Kinnings SL, Xie L, Fung K, Xie L, Bourne PE (2010) The Mycobacterium
tuberculosis Drugome and Its Polypharmacological Implications. PLoS
Comput Biol 6: e100976.
74. Luo H, Chen J, Shi L, Mikailov M, Zhu H, et al. (2011) DRAR-CPI: a server
for identifying drug repositioning potential and adverse drug reactions via the
chemical-protein interactome. Nucleic Acids Res 39: W492–498.
75. Kufareva I, Ilatovskiy AV, Abagyan R (2012) Pocketome: an encyclopedia of
small-molecule binding sites in 4D. Nucleic Acids Res 40: D535–540.
76. Kalinina OV, Wichmann O, Apic G, Russell RB (2012) ProtChemSI: a
network of protein-chemical structural interactions. Nucleic Acids Res 40:
D549–553.
77. Nasr RJ, Swamidass SJ, Baldi PF (2009) Large scale study of multiple-molecule
queries. J Cheminform 1: 7.
78. Swamidass SJ, Azencott CA, Lin TW, Gramajo H, Tsai SC, et al. (2009)
Influence relevance voting: an accurate and interpretable virtual high
throughput screening method. J Chem Inf Model 49: 756–766.
79. Baldi P, Nasr R (2010) When is chemical similarity significant? The statistical
distribution of chemical similarity scores and its extreme values. J Chem Inf
Model 50: 1205–1222.
80. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007)
Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197–
206.
81. Takarabe M, Kotera M, Nishimura Y, Goto S, Yamanishi Y (2012) Drug
target prediction using adverse event report systems: a pharmacogenomic
approach. Bioinformatics 28: i611–i618.
82. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M (2008)
Prediction of drug-target interaction networks from the integration of chemical
and genomic spaces. Bioinformatics 24: i232–240.
83. Nagamine N, Shirakawa T, Minato Y, Torii K, Kobayashi H, et al. (2009)
Integrating statistical predictions and experimental verifications for enhancing
protein-chemical interaction predictions in virtual screening. PLoS Comput
Biol 5: e1000397.
84. Vina D, Uriarte E, Orallo F, Gonzalez-Diaz H (2009) Alignment-free
prediction of a drug-target complex network based on parameters of drug
connectivity and protein sequence of receptors. Mol Pharm 6: 825–835.
85. Gottlieb A, Stein GY, Ruppin E, Sharan R (2011) PREDICT: a method for
inferring novel drug indications with application to personalized medicine. Mol
Syst Biol 7: 496.
86. Cheng F, Liu C, Jiang J, Lu W, Li W, et al. (2012) Prediction of drug-target
interactions and drug repositioning via network-based inference. PLoS Comput
Biol 8: e1002503.
87. Mei JP, Kwoh CK, Yang P, Li XL, Zheng J (2013) Drug-target interaction
prediction by learning from local information and neighbors. Bioinformatics
29: 238–245.
88. van Laarhoven T, Marchiori E (2013) Predicting Drug-Target Interactions for
New Drug Compounds Using a Weighted Nearest Neighbor Profile. PLoS
ONE 8: e66952.
89. Alaimo S, Pulvirenti A, Giugno R, Ferro A (2013) Drug-target interaction
prediction through domain-tuned network-based inference. Bioinformatics 29:
2004–2008.
90. Oprea TI, Nielsen SK, Ursu O, Yang JJ, Taboureau O, et al. (2011)
Associating Drugs, Targets and Clinical Outcomes into an Integrated Network
PLOS Computational Biology | www.ploscompbiol.org 12 May 2014 | Volume 10 | Issue 5 | e1003554
Affords a New Platform for Computer-Aided Drug Repurposing. Mol Inform
30: 100–111.
91. Iacucci E, Tranchevent LC, Popovic D, Pavlopoulos GA, De Moor B, et al.
(2012) ReLiance: a machine learning and literature-based prioritization of
receptor-ligand pairings. Bioinformatics 28: i569–i574.
92. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target
identification using side-effect similarity. Science 321: 263–266.
93. Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, et al. (2010) Drug-
induced regulation of target expression. PLoS Comput Biol 6: e1000925.
94. Chiang AP, Butte AJ (2009) Systematic evaluation of drug-disease relationships
to identify leads for novel drug uses. Clin Pharmacol Ther 86: 507–510.
95. Spitzmuller A, Mestres J (2013) Prediction of the P. falciparum target space
relevant to malaria drug discovery. PLoS Comput Biol 9: e1003257.
96. Xie L, Xie L, Bourne PE (2011) Structure-based systems biology for analyzing
off-target binding. Curr Opin Struct Biol 21: 189–199.
97. Martinez-Jimenez F, Papadatos G, Yang L, Wallace IM, Kumar V, et al.
(2013) Target prediction for an open access set of compounds active against
Mycobacterium tuberculosis. PLoS Comput Biol 9: e1003253.
98. Xie L, Li J, Xie L, Bourne PE (2009) Drug discovery using chemical systems
biology: identification of the protein-ligand binding network to explain the side
effects of CETP inhibitors. PLoS Comput Biol 5: e1000387.
99. Garvie CW, Wolberger C (2001) Recognition of specific DNA sequences. Mol
Cell 8: 937–946.
100. Rohs R, West SM, Sosinsky A, Liu P, Mann RS, et al. (2009) The role of DNA
shape in protein-DNA recognition. Nature 461: 1248–1253.
101. Rohs R, West SM, Liu P, Honig B (2009) Nuance in the double-helix and its
role in protein-DNA recognition. Curr Opin Struct Biol 19: 171–177.
102. Eldar A, Elowitz MB (2010) Functional roles for noise in genetic circuits.
Nature 467: 167–173.
103. Lemerle C, Di Ventura B, Serrano L (2005) Space as the final frontier in
stochastic simulations of biological systems. FEBS Lett 579: 1789–1794.
104. Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK (2006) Physicochemical
modelling of cell signalling pathways. Nat Cell Biol 8: 1195–1203.
105. Araujo RP, Petricoin EF, Liotta LA (2005) A mathematical model of
combination therapy using the EGFR signaling network. Biosystems 80: 57–69.
106. Araujo RP, Liotta LA, Petricoin EF (2007) Proteins, drug targets and the
mechanisms they control: the simple truth about complex networks. Nat Rev
Drug Discov 6: 871–880.
107. Yang K, Bai H, Ouyang Q, Lai L, Tang C (2008) Finding multiple target
optimal intervention in disease-related molecular network. Mol Syst Biol 4:
228.
108. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT (2010) Identification of
optimal drug combinations targeting cellular networks: integrating phospho-
proteomics and computational network analysis. Cancer Res 70: 6704–6714.
109. Qi X (2006) Stochastic models for prodrug targeting. 1. Diffusion of the efflux
drug. Mol Pharm 3: 187–195.
110. Khalili S, Monaco JM, Armaou A (2010) Development of a stochastic model
for the efficacy of NRTIs using known mechanisms of action. J Theor Biol 265:
704–717.
111. Stein M, Gabdoulline RR, Wade RC (2007) Bridging from molecular
simulation to biochemical networks. Curr Opin Struct Biol 17: 166–172.
112. Warshel A, Sharma PK, Kato M, Xiang Y, Liu H, et al. (2006) Electrostatic
basis for enzyme catalysis. Chem Rev 106: 3210–3235.
113. Wade RC, Gabdoulline RR, Ludemann SK, Lounnas V (1998) Electrostatic
steering and ionic tethering in enzyme-ligand binding: insights from
simulations. Proc Natl Acad Sci U S A 95: 5942–5949.
114. Gabdoulline RR, Stein M, Wade RC (2007) qPIPSA: relating enzymatic
kinetic parameters and interaction fields. BMC Bioinformatics 8: 373.
115. Dell’Orco D (2009) Fast predictions of thermodynamics and kinetics of protein-
protein recognition from structures: from molecular design to systems biology.
Mol Biosyst 5: 323–334.
116. Bai H, Yang K, Yu D, Zhang C, Chen F, et al. (2011) Predicting kinetic
constants of protein-protein interactions based on structural properties.
Proteins 79: 720–734.
117. Moal IH, Bates PA (2012) Kinetic rate constant prediction supports the
conformational selection mechanism of protein binding. PLoS Comput Biol 8:
e1002351.
118. Ren J, Xie L, Li WW, Bourne PE (2010) SMAP-WS: a parallel web service for
structural proteome-wide ligand-binding site comparison. Nucleic Acids Res 38
Suppl: W441–444.
119. Xie L, Bourne PE (2009) A unified statistical model to support local sequence
order independent similarity searching for ligand-binding sites and its
application to genome-based drug discovery. Bioinformatics 25: i305–312.
120. Xie L, Bourne PE (2008) Detecting evolutionary relationships across existing
fold space, using sequence order-independent profile-profile alignments. Proc
Natl Acad Sci U S A 105: 5441–5446.
121. Xie L, Bourne PE (2007) A robust and efficient algorithm for the shape
description of protein structures and its application in predicting ligand binding
sites. BMC Bioinformatics 8 Suppl 4: S9.
122. Hermann JC, Marti-Arbona R, Fedorov AA, Fedorov E, Almo SC, et al. (2007)
Structure-based activity prediction for an enzyme of unknown function. Nature
448: 775–779.
123. Bulik S, Grimbs S, Huthmacher C, Selbig J, Holzhutter HG (2009) Kinetic
hybrid models composed of mechanistic and simplified enzymatic rate laws–a
promising method for speeding up the kinetic modelling of complex metabolic
networks. FEBS J 276: 410–424.
124. Nam H, Lewis NE, Lerman JA, Lee DH, Chang RL, et al. (2012) Network
context and selection in the evolution to enzyme specificity. Science 337: 1101–
1104.
125. Wu Y, Vendome J, Shapiro L, Ben-Shaul A, Honig B (2011) Transforming
binding affinities from three dimensions to two with application to cadherin
clustering. Nature 475: 510–513.
126. Kenakin T, Christopoulos A (2013) Signalling bias in new drug discovery:
detection, quantification and therapeutic impact. Nat Rev Drug Discov 12:
205–216.
127. Bruning JB, Parent AA, Gil G, Zhao M, Nowak J, et al. (2010) Coupling of
receptor conformation and ligand orientation determine graded activity. Nat
Chem Biol 6: 837–843.
128. Kojetin DJ, Burris TP (2013) Small molecule modulation of nuclear receptor
conformational dynamics: implications for function and drug discovery. Mol
Pharmacol 83: 1–8.
129. Amaro RE, Baron R, McCammon JA (2008) An improved relaxed complex
scheme for receptor flexibility in computer-aided drug design. J Comput Aided
Mol Des 22: 693–705.
130. Kobilka BK, Gether U (2002) Use of fluorescence spectroscopy to study
conformational changes in the beta 2-adrenoceptor. Methods Enzymol 343:
170–182.
131. Hruby VJ, Tollin G (2007) Plasmon-waveguide resonance (PWR) spectroscopy
for directly viewing rates of GPCR/G-protein interactions and quantifying
affinities. Curr Opin Pharmacol 7: 507–514.
132. Lohse MJ, Hein P, Hoffmann C, Nikolaev VO, Vilardaga JP, et al. (2008)
Kinetics of G-protein-coupled receptor signals in intact cells. Br J Pharmacol
153 Suppl 1: S125–132.
133. Baneres JL, Mesnier D, Martin A, Joubert L, Dumuis A, et al. (2005) Molecular
characterization of a purified 5-HT4 receptor: a structural basis for drug
efficacy. J Biol Chem 280: 20253–20260.
134. Okada T, Palczewski K (2001) Crystal structure of rhodopsin: implications for
vision and beyond. Curr Opin Struct Biol 11: 420–426.
135. Pellissier LP, Sallander J, Campillo M, Gaven F, Queffeulou E, et al. (2009)
Conformational toggle switches implicated in basal constitutive and agonist-
induced activated states of 5-hydroxytryptamine-4 receptors. Mol Pharmacol
75: 982–990.
136. Liu JJ, Horst R, Katritch V, Stevens RC, Wuthrich K (2012) Biased signaling
pathways in beta2-adrenergic receptor characterized by 19F-NMR. Science
335: 1106–1110.
137. Gelis L, Wolf S, Hatt H, Neuhaus EM, Gerwert K (2012) Prediction of a
ligand-binding niche within a human olfactory receptor by combining site-
directed mutagenesis with dynamic homology modeling. Angew Chem Int Ed
Engl 51: 1274–1278.
138. Taddese B, Simpson LM, Wall ID, Blaney FE, Kidley NJ, et al. (2012) G-
protein-coupled receptor dynamics: dimerization and activation models
compared with experiment. Biochem Soc Trans 40: 394–399.
139. Li CY, Yu Q, Ye ZQ, Sun Y, He Q, et al. (2007) A nonsynonymous SNP in
human cytosolic sialidase in a small Asian population results in reduced enzyme
activity: potential link with severe adverse reactions to oseltamivir. Cell Res 17:
357–362.
140. Kowarsch A, Fuchs A, Frishman D, Pagel P (2010) Correlated mutations: a
hallmark of phenotypic amino acid substitutions. PLoS Comput Biol 6:
e1000923.
141. Lockless SW, Ranganathan R (1999) Evolutionarily conserved pathways of
energetic connectivity in protein families. Science 286: 295–299.
142. Dekker JP, Fodor A, Aldrich RW, Yellen G (2004) A perturbation-based
method for calculating explicit likelihood of evolutionary co-variance in
multiple sequence alignments. Bioinformatics 20: 1565–1572.
143. Skerker JM, Perchuk BS, Siryaporn A, Lubin EA, Ashenberg O, et al. (2008)
Rewiring the specificity of two-component signal transduction systems. Cell
133: 1043–1054.
144. Lee J, Natarajan M, Nashine VC, Socolich M, Vo T, et al. (2008) Surface sites
for engineering allosteric control in proteins. Science 322: 438–442.
145. Lee SY, Banerjee A, MacKinnon R (2009) Two separate interfaces between the
voltage sensor and pore are required for the function of voltage-dependent K(+)
channels. PLoS Biol 7: e47.
146. Ferguson AD, Amezcua CA, Halabi NM, Chelliah Y, Rosen MK, et al. (2007)
Signal transduction pathway of TonB-dependent transporters. Proc Natl Acad
Sci U S A 104: 513–518.
147. Zheng W, Brooks B (2005) Identification of dynamical correlations within the
myosin motor domain by the normal mode analysis of an elastic network
model. J Mol Biol 346: 745–759.
148. Zheng W, Liao JC, Brooks BR, Doniach S (2007) Toward the mechanism of
dynamical couplings and translocation in hepatitis C virus NS3 helicase using
elastic network model. Proteins 67: 886–896.
149. Pan H, Lee JC, Hilser VJ (2000) Binding sites in Escherichia coli dihydrofolate
reductase communicate by modulating the conformational ensemble. Proc Natl
Acad Sci U S A 97: 12020–12025.
150. Chennubhotla C, Bahar I (2006) Markov propagation of allosteric effects in
biomolecular systems: application to GroEL-GroES. Mol Syst Biol 2: 36.
PLOS Computational Biology | www.ploscompbiol.org 13 May 2014 | Volume 10 | Issue 5 | e1003554
151. del Sol A, Fujihashi H, Amoros D, Nussinov R (2006) Residues crucial for
maintaining short paths in network communication mediate signaling in
proteins. Mol Syst Biol 2: 2006 0019.
152. Saalau-Bethell SM, Woodhead AJ, Chessari G, Carr MG, Coyle J, et al. (2012)
Discovery of an allosteric mechanism for the regulation of HCV NS3 protein
function. Nat Chem Biol 8: 920–925.
153. Gleeson MP, Hersey A, Montanari D, Overington J (2011) Probing the links
between in vitro potency, ADMET and physicochemical parameters. Nat Rev
Drug Discov 10: 197–208.
154. Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time
and its implications for lead optimization. Nat Rev Drug Discov 5: 730–739.
155. Lu H, Tonge PJ (2010) Drug-target residence time: critical information for lead
optimization. Curr Opin Chem Biol 14: 467–474.
156. Braz VA, Holladay LA, Barkley MD (2010) Efavirenz binding to HIV-1 reverse
transcriptase monomers and dimers. Biochemistry 49: 601–610.
157. Lu H, England K, am Ende C, Truglio JJ, Luckner S, et al. (2009) Slow-onset
inhibition of the FabI enoyl reductase from francisella tularensis: residence time
and in vivo activity. ACS Chem Biol 4: 221–231.
158. Copeland RA (2011) Conformational adaptation in drug-target interactions
and residence time. Future Med Chem 3: 1491–1501.
159. Vauquelin G, Charlton SJ (2010) Long-lasting target binding and rebinding as
mechanisms to prolong in vivo drug action. Br J Pharmacol 161: 488–508.
160. Carroll MJ, Mauldin RV, Gromova AV, Singleton SF, Collins EJ, et al. (2012)
Evidence for dynamics in proteins as a mechanism for ligand dissociation. Nat
Chem Biol 8: 246–252.
161. ElSawy KM, Twarock R, Lane DP, Verma CS, Caves LSD (2012)
Characterization of the Ligand Receptor Encounter Complex and Its Potential
for in Silico Kinetics-Based Drug Development. J Chem Theory Comput 8:
314–321.
162. Laio A, Gervasio FL (2008) Metadynamics: a method to simulate rare events
and reconstruct the free energy in biophysics, chemistry and material science.
Rep Prog Phys 71.
163. Pietrucci F, Marinelli F, Carloni P, Laio A (2009) Substrate Binding
Mechanism of HIV-1 Protease from Explicit-Solvent Atomistic Simulations.
J Am Chem Soc 131: 11811–11818.
164. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and
combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458–
466.
165. Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, et al. (2012)
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.
Nat Chem Biol 8: 905–912.
166. Huang J, Niu C, Green CD, Yang L, Mei H, et al. (2013) Systematic Prediction
of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Inter-
action Network. PLoS Comput Biol 9: e1002998.
167. Gottlieb A, Stein GY, Oron Y, Ruppin E, Sharan R (2012) INDI: a
computational framework for inferring drug interactions and their associated
recommendations. Mol Syst Biol 8: 592.
168. Tatonetti NP, Ye PP, Daneshjou R, Altman RB (2012) Data-driven prediction
of drug effects and interactions. Sci Transl Med 4: 125ra131.
169. Hansch C, Leo A, Mekapati SB, Kurup A (2004) QSAR and ADME. Bioorg
Med Chem 12: 3391–3400.
170. Hou T, Wang J, Zhang W, Wang W, Xu X (2006) Recent advances in
computational prediction of drug absorption and permeability in drug
discovery. Curr Med Chem 13: 2653–2667.
171. Nettles JH, Jenkins JL, Williams C, Clark AM, Bender A, et al. (2007) Flexible
3D pharmacophores as descriptors of dynamic biological space. J Mol Graph
Model 26: 622–633.
172. Moroy G, Martiny VY, Vayer P, Villoutreix BO, Miteva MA (2012) Toward in
silico structure-based ADMET prediction in drug discovery. Drug Discov
Today 17: 44–55.
173. Schlessinger A, Geier E, Fan H, Irwin JJ, Shoichet BK, et al. (2011) Structure-
based discovery of prescription drugs that interact with the norepinephrine
transporter, NET. Proc Natl Acad Sci U S A 108: 15810–15815.
174. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, et al. (2009) PubChem: a public
information system for analyzing bioactivities of small molecules. Nucleic Acids
Res 37: W623–633.
175. Epstein SL, Yu X, Xie L (2013) Multi-agent, multi-case-based reasoning.
Lecture Note in Comp Sci 7969: 74–88.
176. Sun H, Scott DO (2010) Structure-based drug metabolism predictions for drug
design. Chem Biol Drug Des 75: 3–17.
177. Nebert DW, Jorge-Nebert L, Vesell ES (2003) Pharmacogenomics and
‘‘individualized drug therapy’’: high expectations and disappointing achieve-
ments. Am J Pharmacogenomics 3: 361–370.
178. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug
metabolism: Regulation of gene expression, enzyme activities, and impact of
genetic variation. Pharmacol Ther 138: 103–141.
179. Honkakoski P, Negishi M (2000) Regulation of cytochrome P450 (CYP) genes
by nuclear receptors. Biochem J 347: 321–337.
180. Scotto KW (2003) Transcriptional regulation of ABC drug transporters.
Oncogene 22: 7496–7511.
181. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, et al. (2010)
SuperCYP: a comprehensive database on Cytochrome P450 enzymes including
a tool for analysis of CYP-drug interactions. Nucleic Acids Res 38: D237–243.
182. Zhang QY (2009) Genome-wide off-target binding of Rifampin and its
implications for genetic disposition to drug toxicity. M.S. Thesis, The
University of York.
183. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, et al. (2004)
Comparison of cytochrome P450 (CYP) genes from the mouse and human
genomes, including nomenclature recommendations for genes, pseudogenes
and alternative-splice variants. Pharmacogenetics 14: 1–18.
184. Poliseno L (2012) Pseudogenes: newly discovered players in human cancer. Sci
Signal 5: re5.
185. Wang J, Pitarque M, Ingelman-Sundberg M (2006) 39-UTR polymorphism in
the human CYP2A6 gene affects mRNA stability and enzyme expression.
Biochem Biophys Res Commun 340: 491–497.
186. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK (2009)
Pharmacometabonomic identification of a significant host-microbiome meta-
bolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A
106: 14728–14733.
187. Diaz Ochoa JG, Bucher J, Pery AR, Zaldivar Comenges JM, Niklas J, et al.
(2012) A multi-scale modeling framework for individualized, spatiotemporal
prediction of drug effects and toxicological risk. Front Pharmacol 3: 204.
188. Thorn CF, Klein TE, Altman RB (2005) PharmGKB: the pharmacogenetics
and pharmacogenomics knowledge base. Methods Mol Biol 311: 179–191.
189. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. (2009)
Estimation of the warfarin dose with clinical and pharmacogenetic data.
N Engl J Med 360: 753–764.
190. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells.
Nature 483: 570–575.
191. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al.
(2012) The Cancer Cell Line Encyclopedia enables predictive modelling of
anticancer drug sensitivity. Nature 483: 603–607.
192. Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, et al. (2007) Kinase mutations
and imatinib mesylate response for 64 Taiwanese with advanced GIST:
preliminary experience from Chang Gung Memorial Hospital. Ann Surg
Oncol 14: 1123–1128.
193. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
N Engl J Med 352: 786–792.
194. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired
resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med 2: e73.
195. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ (2009) Absorption of
montelukast is transporter mediated: a common variant of OATP2B1 is
associated with reduced plasma concentrations and poor response. Pharma-
cogenet Genomics 19: 129–138.
196. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, et al.
(2010) Association of KRAS p.G13D mutation with outcome in patients with
chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
JAMA 304: 1812–1820.
197. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, et al. (2001)
Integrating genotype and phenotype information: an overview of the
PharmGKB project. Pharmacogenetics Research Network and Knowledge
Base. Pharmacogenomics J 1: 167–170.
198. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-
type KRAS is required for panitumumab efficacy in patients with metastatic
colorectal cancer. J Clin Oncol 26: 1626–1634.
199. Andre T, Blons H, Mabro M, Chibaudel B, Bachet JB, et al. (2013)
Panitumumab combined with irinotecan for patients with KRAS wild-type
metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR
efficacy, tolerance, and translational molecular study. Ann Oncol 24: 412–419.
200. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. (2012) An
integrated map of genetic variation from 1,092 human genomes. Nature 491:
56–65.
201. Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, et al. (2012) An
integrated encyclopedia of DNA elements in the human genome. Nature 489:
57–74.
202. Gerstein MB, Lu ZJ, Van Nostrand EL, Cheng C, Arshinoff BI, et al. (2011)
Integrative analysis of the Caenorhabditis elegans genome by the modEN-
CODE project. Science 330: 1775–1787.
203. Muers M (2011) Functional genomics: the modENCODE guide to the genome.
Nat Rev Genet 12: 80.
204. Roy S, Ernst J, Kharchenko PV, Kheradpour P, Negre N, et al. Identification
of functional elements and regulatory circuits by Drosophila modENCODE.
Science 330: 1787–1797.
205. Davidson EH, Rast JP, Oliveri P, Ransick A, Calestani C, et al. (2002) A
genomic regulatory network for development. Science 295: 1669–1678.
206. Patwardhan RP, Hiatt JB, Witten DM, Kim MJ, Smith RP, et al. (2012)
Massively parallel functional dissection of mammalian enhancers in vivo. Nat
Biotechnol 30: 265–270.
207. Sharon E, Kalma Y, Sharp A, Raveh-Sadka T, Levo M, et al. (2012) Inferring
gene regulatory logic from high-throughput measurements of thousands of
systematically designed promoters. Nat Biotechnol 30: 521–530.
208. Melnikov A, Murugan A, Zhang X, Tesileanu T, Wang L, et al. (2012)
Systematic dissection and optimization of inducible enhancers in human cells
using a massively parallel reporter assay. Nat Biotechnol 30: 271–277.
PLOS Computational Biology | www.ploscompbiol.org 14 May 2014 | Volume 10 | Issue 5 | e1003554
209. Kinney JB, Murugan A, Callan CG, Jr., Cox EC (2010) Using deep sequencing
to characterize the biophysical mechanism of a transcriptional regulatory
sequence. Proc Natl Acad Sci U S A 107: 9158–9163.
210. Shi Z, Moult J (2011) Structural and functional impact of cancer-related
missense somatic mutations. J Mol Biol 413: 495–512.
211. Wang Z, Moult J (2001) SNPs, protein structure, and disease. Human
Mutation 17: 263–270.
212. Xie L, Ng C, Ali T, Valencia R, Ferreira BL, et al. (2013) Multiscale Modeling
of the Causal Functional Roles of nsSNPs in a Genome-Wide Association
Study: Application to Hypoxia. BMC Genomics 14: S9.
213. David A, Razali R, Wass MN, Sternberg MJ (2012) Protein-protein interaction
sites are hot spots for disease-associated nonsynonymous SNPs. Hum Mutat 33:
359–363.
214. Stein A, Mosca R, Aloy P (2011) Three-dimensional modeling of protein
interactions and complexes is going ’omics. Curr Opin Struct Biol 21: 200–208.
215. Stranger BE, Stahl EA, Raj T (2010) Progress and promise of genome-wide
association studies for human complex trait genetics. Genetics 187: 367–383.
216. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005)
Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
217. Knight J, Barnes MR, Breen G, Weale ME (2011) Using functional annotation
for the empirical determination of Bayes Factors for genome-wide association
study analysis. PLoS ONE 6: e14808.
218. Lee I, Blom UM, Wang PI, Shim JE, Marcotte EM (2011) Prioritizing
candidate disease genes by network-based boosting of genome-wide association
data. Genome Res 21: 1109–1121.
219. Huang SS, Clarke DC, Gosline SJ, Labadorf A, Chouinard CR, et al. (2013)
Linking proteomic and transcriptional data through the interactome and
epigenome reveals a map of oncogene-induced signaling. PLoS Comput Biol 9:
e1002887.
220. Huang SS, Fraenkel E (2009) Integrating proteomic, transcriptional, and
interactome data reveals hidden components of signaling and regulatory
networks. Sci Signal 2: ra40.
221. Cheng TM, Goehring L, Jeffery L, Lu YE, Hayles J, et al. (2012) A structural
systems biology approach for quantifying the systemic consequences of
missense mutations in proteins. PLoS Comput Biol 8: e1002738.
222. Dessailly BH, Nair R, Jaroszewski L, Fajardo JE, Kouranov A, et al. (2009) PSI-2:
structural genomics to cover protein domain family space. Structure 17: 869–881.
223. Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, et al. (2013) The
GPCR Network: a large-scale collaboration to determine human GPCR
structure and function. Nat Rev Drug Discov 12: 25–34.
224. Jin MS, Oldham ML, Zhang Q, Chen J (2012) Crystal structure of the
multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature
490: 566–569.
225. Korkhov VM, Mireku SA, Locher KP (2012) Structure of AMP-PNP-bound
vitamin B12 transporter BtuCD-F. Nature 490: 367–372.
226. Gopinath K, Venclovas C, Ioerger TR, Sacchettini JC, McKinney JD, et al.
(2013) A vitamin B(1)(2) transporter in Mycobacterium tuberculosis. Open Biol
3: 120175.
227. Berman HM, Coimbatore Narayanan B, Costanzo LD, Dutta S, Ghosh S, et
al. (2013) Trendspotting in the Protein Data Bank. FEBS Lett 587: 1036–1045.
228. Kryshtafovych A, Fidelis K, Moult J (2011) CASP9 results compared to those of
previous CASP experiments. Proteins 79 Suppl 10: 196–207.
229. Marks DS, Colwell LJ, Sheridan R, Hopf TA, Pagnani A, et al. (2011) Protein
3D structure computed from evolutionary sequence variation. PLoS ONE 6:
e28766.
230. Ward AB, Sali A, Wilson IA (2013) Biochemistry. Integrative structural
biology. Science 339: 913–915.
231. Tseng YY, Chen ZJ, Li WH (2010) fPOP: footprinting functional pockets of
proteins by comparative spatial patterns. Nucleic Acids Res 38: D288–295.
232. Gao M, Skolnick J (2013) APoc: large-scale identification of similar protein
pockets. Bioinformatics 29: 597–604.
233. Liu T, Altman RB (2011) Using multiple microenvironments to find similar
ligand-binding sites: application to kinase inhibitor binding. PLoS Comput Biol
7: e1002326.
234. Bryant DH, Moll M, Finn PW, Kavraki LE (2013) Combinatorial clustering of
residue position subsets predicts inhibitor affinity across the human kinome.
PLoS Comput Biol 9: e1003087.
235. Milletti F, Vulpetti A (2010) Predicting polypharmacology by binding site
similarity: from kinases to the protein universe. J Chem Inf Model 50: 1418–
1431.
236. Sael L, Kihara D (2012) Detecting local ligand-binding site similarity in
nonhomologous proteins by surface patch comparison. Proteins 80: 1177–
1195.
237. Ramensky V, Sobol A, Zaitseva N, Rubinov A, Zosimov V (2007) A novel
approach to local similarity of protein binding sites substantially improves
computational drug design results. Proteins 69: 349–357.
238. Xiong B, Wu J, Burk DL, Xue M, Jiang H, et al. (2010) BSSF: a fingerprint
based ultrafast binding site similarity search and function analysis server. BMC
Bioinformatics 11: 47.
PLOS Computational Biology | www.ploscompbiol.org 15 May 2014 | Volume 10 | Issue 5 | e1003554
